AstraZeneca has announced that its drug Lynparza has demonstrated a strong safety and efficacy performance in a phase III breast cancer trial.
Data from the OlympiAD trial showed a statistically significant and clinically meaningful improvement in progression-free survival for BRCA-mutated metastatic breast cancer treated with Lynparza.
“AstraZeneca has reported new clinical data showing the effectiveness of Lynparza as a treatment for BRCA-mutated metastatic breast cancer.“
AstraZeneca's tablet-based therapy performed better than standard of care chemotherapy treatment, meaning the drug was able to meet its primary endpoint in the trial. It was also shown that patients treated with Lynparza had a 42 percent lower risk of their disease worsening or death compared to those who received chemotherapy.
Additionally, the overall safety profile of the drug was indicated to be consistent with previous trials of Lynparza.
Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said this "represents an important milestone for Lynparza, as this is the first positive phase III trial in which a PARP inhibitor has shown a significant benefit for patients outside of ovarian cancer".
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical